This segment focuses on providing genetic testing services related to reproductive health. BGI Genomics offers non-invasive prenatal testing (NIPT) to screen for chromosomal abnormalities in fetuses, as well as preimplantation genetic testing (PGT) to screen embryos for genetic disorders before implantation. The company utilizes advanced sequencing technologies and bioinformatics to analyze cell-free DNA (cfDNA) from maternal blood samples. This segment addresses the needs of expectant parents and fertility clinics, improving outcomes and reducing the risk of genetic diseases. Market positioning is strong in China and expanding internationally, with collaborations with leading healthcare providers. Future opportunities include expanding the range of tests and improving accuracy. Regulatory compliance is crucial, with adherence to guidelines from health authorities. Partnerships with Natera for oncology testing in China are also in place.

BGI Genomics' oncology segment provides comprehensive genomic solutions for cancer research, diagnosis, and treatment. This includes genomic sequencing services for tumor profiling, liquid biopsy tests for early cancer detection and monitoring, and companion diagnostics to guide treatment decisions. The company utilizes next-generation sequencing (NGS) and other advanced technologies to analyze tumor samples and identify genetic mutations. This segment addresses the needs of oncologists, researchers, and patients, improving cancer detection rates and enabling personalized treatment approaches. Market positioning is strong in China and expanding globally, with partnerships with oncology centers and pharmaceutical companies. Future opportunities include developing new cancer tests and expanding into new therapeutic areas. Regulatory compliance is essential, with adherence to guidelines from health authorities. BGI Americas partners with Champions Oncology to offer mass spectrometry-based proteomics and multiomics data analysis solutions.

This segment encompasses a broad range of clinical sequencing services offered by BGI Genomics. These services include DNA sequencing, RNA sequencing, and customized sequencing solutions for various clinical applications. The company utilizes advanced sequencing platforms and bioinformatics tools to provide accurate and reliable results. This segment serves medical institutions, research institutions, and other healthcare providers, enabling them to diagnose diseases, identify genetic predispositions, and develop personalized treatment plans. Market positioning is strong in China and expanding internationally, with a focus on providing high-quality sequencing services at competitive prices. Future opportunities include expanding the range of sequencing services and developing new diagnostic tests. Regulatory compliance is crucial, with adherence to guidelines from health authorities. BGI Genomics also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19.